Floatz logo

Repotrectinib

Hormone Receptor-positive Human Epidermal Growth Factor 2-negative

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

116 Active assets in the Hormone Receptor-positive Human Epidermal Growth Factor 2-negative cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

Repotrectinib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
invasive lobular breast carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
ROS1 Gene RearrangementDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →